SUMMIT, PEAK and APEX registration-directed clinical trial enrollment remains on track; topline results expected from all three studies in 2025 Exhibit 99.1 Ended 1Q 2024 with $435.7 million in cash, suf icient to fund operations into 2027 "Our team made important progress in the first quarter," said Andrew Robbins, the Company's President and Chief Executive Officer. "Based on the emerging clinical results demonstrating the potential of bezuclastinib in both systemic mastocytosis and GIST patients, we have ...